Evidence map›Paper›PMID 42257007›Full record

ArticleClinical case reports2026

Meropenem-Induced Possible Mixed Drug-Induced Liver Injury With Cholestatic Evolution: A Case Report Evaluated Using the Updated RUCAM (2016).

Nidal Mutawodeh, Sarah Saife, Akram Shalaby, Kamaleldein Einar, Motasem Kamal, Malik Hijaz, Tariq Hamadneh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nidal MutawodehDepartment of Medicine, Faculty of Medicine and Health Sciences An-Najah National University Nablus Palestine.
Sarah SaifeDepartment of Medicine, Faculty of Medicine and Health Sciences An-Najah National University Nablus Palestine.ORCID https://orcid.org/0009-0001-1323-2682
Akram ShalabyUniversity Hospitals Cleveland Ohio USA.
Kamaleldein EinarDepartment of Lymphoma/Myeloma Anderson Cancer Center Houston Texas USA.
Motasem KamalDepartment of Medicine, Faculty of Medicine and Health Sciences An-Najah National University Nablus Palestine.
Malik HijazDepartment of Medicine, Faculty of Medicine and Health Sciences An-Najah National University Nablus Palestine.
Tariq HamadnehGrand Strand Medical Center Myrtle Beach South Carolina USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced liver injury (DILI) remains a diagnosis of exclusion and requires systematic causality assessment. Meropenem is generally considered hepatically safe; however, rare cases of idiosyncratic DILI have been reported. We describe a 33-year-old female who developed progressive elevation of liver tests following exposure to meropenem. Based on

Indexed as

case reportdrug‐induced liver injurymeropenemmixed liver injuryRUCAM (2016)updated RUCAM

Identifiers

PMID42257007
PMCPMC13239250

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.